Pharmaceutical Microbiology Group

About us


Die ECA Pharmaceutical Microbiology Working Group concentrates on all relevant microbiological questions in the context of the development and manufacturing of pharmaceutical, biopharmaceutical and combination products.

Today

During the last 10 years, the group more and more became the preferential contact point for all microbiological topics, questions from members as well as for requests from authorities. Therefore, the ECA and the Group Advisory Board decided in 2015 to rename the group to Pharmaceutical Microbiology Working Group and to extend its scope and activities. It is now the group’s goal to provide advice with regard to all different subjects in pharmaceutical microbiology.

The current issues of the group are:

  • Giving guidance in pharmaceutical microbiological best practices by writing guidance documents for subjects not covered by the authorities (e.g. guideline for deviation handling in non-sterile production facilities and bacterial endotoxin testing).
  • Providing information on successful growth media concepts
  • Promoting the standardisation for the submission of alternative microbiological methods and pushing the integration of certain RMM methods into the European Pharmacopoeia chapter 5.1.6.
  • Presenting an up-to-date website covering current problems and summarizing relevant publications for pharmaceutical microbiology.
  • Organising education courses, conferences and trainings on relevant microbiological contents

History

The group was founded as Rapid Microbiological Methods (RMM) Working Group on 7 June 2006 at the Paul-Ehrlich-Institut (PEI – the German Federal Agency for Vaccines and Biomedicines) by 11 representatives from the European pharmaceutical industry and the PEI. The working group reviewed the current situation of RMM in Europe. In the following years it supported group members with current information about the development, implementation and validation of RMM. To move forward to a harmonised thinking, the group provided literature lists, best practice papers and guideline lists on its website. It further organised education courses and conferences on RMM and method validation. Moreover, the group submitted member comments to the regulatory authorities.

 

Board of Directors

 
Dr Sven Deutschmann. Chairman:
Dr Sven Deutschmann,

Roche Diagnostics
Dr David Roesti,
Novartis Pharma AG, Switzerland
Björn Breth Dr Björn Breth,
bioMérieux Deutschland
Dr Marcel Goverde. Dr Marcel Goverde,
MGP Consulting und Projektmanagement
Marja Claassen,
MSD, The Netherlands
Olivier Guenec,
Sartorius, France
Barbara Gerten. Barbara Gerten,
Merck KGaA
Dr Ulrich Herber. Dr Ulrich Herber,
Charles River

Authority Advisory Board

The Authority Advisory Board is not part of the legal structure. The Advisory Board Members support the Pharmaceutical Microbiology Working Group on a case by case decision and not for all of its activities. The following Board Members of the ECA Foundation Board support the Pharmaceutical Microbiology Working Group:

 
Priv.-Doz. Dr. Claudius Micha Nübling
World Health Organization (WHO), Geneva
Dr. Isabelle Bekeredjian-Ding Priv.-Doz. Dr. Isabelle Bekeredjian-Ding,
Paul-Ehrlich-Institut (German Federal Institute for Vaccines and Biomedicines)

Please find all Members of the Authority Board of the ECA Foundation.

Imprint   .   Contact us